Search Results

• • 4 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Efficacy of NEDD8 pathway inhibition in preclinical models of poorly differentiated, clinically aggressive colorectal cancer

  Authors:Gabriele Picco, Consalvo Petti, Francesco Sassi, Katia Grillone, Giorgia Migliardi, Teresa Rossi, et al.From:Journal of the National Cancer Institute (Vol. 109, Issue 2) Peer-Reviewed

  Feb. 13, 2017302 words Author abstract, Rep...

   Abstract Only

• Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens

  Authors:Fiona M. Behan, Francesco Iorio, Gabriele Picco, Emanuel Goncalves, Charlotte M. Beaver, Giorgia Migliardi, et al.From:Nature (Vol. 568, Issue 7753) Peer-Reviewed

  Apr. 201910,845 words Report 1620LFunctional genomics approaches can overcome limitations--such as the lack of identification of robust targets and poor clinical efficacy--that hamper cancer drug development. Here we performed genome-scale CRISPR-Cas9...

• Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models

  Authors:Valentina Belli, Nunzia Matrone, Stefania Napolitano, Giorgia Migliardi, Francesca Cottino, Andrea Bertotti, et al.From:Journal of Experimental & Clinical Cancer Research (Vol. 38, Issue 1) Peer-Reviewed

  June 4, 20197,723 words Report 1610LBackground Targeting the epidermal growth factor receptor (EGFR) either alone or in combination with chemotherapy is an effective treatment for patients with RAS wild-type metastatic colorectal cancer (mCRC)....

• The genomic landscape of response to EGFR blockade in colorectal cancer

  Authors:Andrea Bertotti, Eniko Papp, Sian Jones, Vilmos Adleff, Valsamo Anagnostou, Barbara Lupo, et al.From:Nature (Vol. 526, Issue 7572) Peer-Reviewed

  Oct. 8, 20157,469 words Report 1570LColorectal cancer is the third most common cancer worldwide, with 1.2 million patients diagnosed annually. In late-stage colorectal cancer, the most commonly used targeted therapies are the monoclonal antibodies...